Elevance Health (ELV) News Today

Elevance Health, Inc. (ELV) shares have moved in response to mixed Q2 results, guidance cuts and broader market trends.

• Positive Sentiment: Analysts maintain bullish stance despite lowered targets – Truist Financial kept a “buy” rating and set a new $440 price target, and brokerages’ consensus sits at $495.80. Truist Financial Lowers Target Consensus Price Target
• Neutral Sentiment: Broader U.S. equities rallied on a solid June retail-sales report, underlining continued consumer spending strength. S&P 500 Gains Today
• Negative Sentiment: Q2 earnings per share of $8.84 missed the $9.30 consensus (–12.6% y/y), as Medicaid and ACA medical-cost inflation weighed on profitability. Zacks Q2 Earnings Miss
• Negative Sentiment: Revenue of $49.42 billion beat estimates, but net margin slipped to 3.23% and EPS guidance was cut to approximately $30 for 2025, citing persistent high medical costs. Reuters: Forecast Cut
• Negative Sentiment: Shares gapped down roughly 7% in premarket trading and have fallen following the weak Q2 print and guidance cut. MarketBeat: Shares Gap Down
• Negative Sentiment: Investors highlighted slower rate alignment in Medicaid and industry-wide cost trends during the Q2 earnings call. Earnings Call Transcript